INSTITUTION'S PROFILE
Limpopo Clinical Research Initiative, Thabazimbi, South Africa.
Publications (1)
Immunogenicity and safety of a SARS-CoV-2 recombinant spike protein nanoparticle vaccine in people living with and without HIV-1 infection: a randomised, controlled, phase 2A/2B trial.
Journal: The lancet. HIV
Publication date: 2022
Journal: The lancet. HIV
Publication Year: 2022